Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators
This review summarizes recent progress and developments as well as the most important pitfalls in targeted alpha-particle therapy, covering single alpha-particle emitters as well as in vivo alpha-particle generators. It discusses the production of radionuclides like 211At, 223Ra, 225Ac/213Bi, labell...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-03-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | http://www.mdpi.com/1420-3049/23/3/581 |
| _version_ | 1828850481193025536 |
|---|---|
| author | Ján Kozempel Olga Mokhodoeva Martin Vlk |
| author_facet | Ján Kozempel Olga Mokhodoeva Martin Vlk |
| author_sort | Ján Kozempel |
| collection | DOAJ |
| description | This review summarizes recent progress and developments as well as the most important pitfalls in targeted alpha-particle therapy, covering single alpha-particle emitters as well as in vivo alpha-particle generators. It discusses the production of radionuclides like 211At, 223Ra, 225Ac/213Bi, labelling and delivery employing various targeting vectors (small molecules, chelators for alpha-emitting nuclides and their biomolecular targets as well as nanocarriers), general radiopharmaceutical issues, preclinical studies, and clinical trials including the possibilities of therapy prognosis and follow-up imaging. Special attention is given to the nuclear recoil effect and its impacts on the possible use of alpha emitters for cancer treatment, proper dose estimation, and labelling chemistry. The most recent and important achievements in the development of alpha emitters carrying vectors for preclinical and clinical use are highlighted along with an outlook for future developments. |
| first_indexed | 2024-12-12T23:12:44Z |
| format | Article |
| id | doaj.art-6e71a6a8a2df475caed62c74f5ac044f |
| institution | Directory Open Access Journal |
| issn | 1420-3049 |
| language | English |
| last_indexed | 2024-12-12T23:12:44Z |
| publishDate | 2018-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Molecules |
| spelling | doaj.art-6e71a6a8a2df475caed62c74f5ac044f2022-12-22T00:08:33ZengMDPI AGMolecules1420-30492018-03-0123358110.3390/molecules23030581molecules23030581Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo GeneratorsJán Kozempel0Olga Mokhodoeva1Martin Vlk2Czech Technical University in Prague, Faculty of Nuclear Sciences and Physical Engineering, Prague CZ-11519, Czech RepublicVernadsky Institute of Geochemistry and Analytical Chemistry, Moscow 119991, RussiaCzech Technical University in Prague, Faculty of Nuclear Sciences and Physical Engineering, Prague CZ-11519, Czech RepublicThis review summarizes recent progress and developments as well as the most important pitfalls in targeted alpha-particle therapy, covering single alpha-particle emitters as well as in vivo alpha-particle generators. It discusses the production of radionuclides like 211At, 223Ra, 225Ac/213Bi, labelling and delivery employing various targeting vectors (small molecules, chelators for alpha-emitting nuclides and their biomolecular targets as well as nanocarriers), general radiopharmaceutical issues, preclinical studies, and clinical trials including the possibilities of therapy prognosis and follow-up imaging. Special attention is given to the nuclear recoil effect and its impacts on the possible use of alpha emitters for cancer treatment, proper dose estimation, and labelling chemistry. The most recent and important achievements in the development of alpha emitters carrying vectors for preclinical and clinical use are highlighted along with an outlook for future developments.http://www.mdpi.com/1420-3049/23/3/581targeted alpha therapynuclear recoilin vivo generatorsradium223Raactiniumastatinebismuthalpha particledecay |
| spellingShingle | Ján Kozempel Olga Mokhodoeva Martin Vlk Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators Molecules targeted alpha therapy nuclear recoil in vivo generators radium 223Ra actinium astatine bismuth alpha particle decay |
| title | Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators |
| title_full | Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators |
| title_fullStr | Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators |
| title_full_unstemmed | Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators |
| title_short | Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators |
| title_sort | progress in targeted alpha particle therapy what we learned about recoils release from in vivo generators |
| topic | targeted alpha therapy nuclear recoil in vivo generators radium 223Ra actinium astatine bismuth alpha particle decay |
| url | http://www.mdpi.com/1420-3049/23/3/581 |
| work_keys_str_mv | AT jankozempel progressintargetedalphaparticletherapywhatwelearnedaboutrecoilsreleasefrominvivogenerators AT olgamokhodoeva progressintargetedalphaparticletherapywhatwelearnedaboutrecoilsreleasefrominvivogenerators AT martinvlk progressintargetedalphaparticletherapywhatwelearnedaboutrecoilsreleasefrominvivogenerators |